SynthesisBMJ open respiratory research2024
Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis.
Synthesis in BMJ open respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.BMJ open respiratory research · 2026Pooled it
- Efficacy of higher-dose versus lower-dose corticosteroids in community-acquired pneumonia: a systematic review and network meta-analysis.Critical care (London, England) · 2026Pooled it
- Efficacy and safety of glucocorticoids therapy of severe community-acquired pneumonia in older adults: a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.The New England journal of medicine · 2025Trial
- Trial
- Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.Intensive care medicine · 2025Trial
- Hydrocortisone vs. Methylprednisolone in Community-Acquired Pneumonia: A Propensity Score Matching Study.Journal of clinical medicine · 2026Article
- Comprehensive analysis of factors to consider when using glucocorticoids for sCAP: A review.Medicine · 2026Review
- Individualized treatment rule for early steroid use in hospitalized patients with community acquired pneumonia: a cohort study.Pneumonia (Nathan Qld.) · 2025Article
- Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis.BMC pulmonary medicine · 2025Article
- Pneumonia: Recent Updates on Diagnosis and Treatment.Microorganisms · 2025Review
- Efficacy and safety of reduning injection for severe pneumonia: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Review
- Myasthenia gravis and community-acquired pneumonia: therapeutic challenges.Frontiers in pharmacology · 2025Review
- Steroids in severe community-acquired pneumonia.Breathe (Sheffield, England) · 2024Article
- Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia.Pneumonia (Nathan Qld.) · 2024Article
- Steroids in the Management of Ionotropic-Resistant Septic Shock: A Comprehensive Review of Efficacy and Outcomes.Cureus · 2024Review
- A pragmatic randomized controlled trial of standard care versus corticosteroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA).Wellcome open research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRandomised controlled trials (RCTs) have demonstrated conflicting results regarding the effects of corticosteroids on the treatment of severe community-acquired pneumonia (CAP). We aimed to investigate the efficacy and safety of different corticosteroids on patients who were hospitalised for severe CAP.
methodsWe performed a systematic search through PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus from inception to May 2023. The primary outcome was all-cause mortality. Data analysis was performed using a random-effects model.
resultsA total of 10 RCTs comprising 1962 patients were included. Corticosteroids were associated with a lower rate of all-cause mortality (risk ratio (RR), 0.70 (95% CI 0.54 to 0.90); I
conclusionsThe use of hydrocortisone, but not other types of corticosteroids, was associated with a reduction in mortality and improvement in pneumonia outcomes among patients hospitalised with severe CAP.PROSPERO registration numberCRD42023431360.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.